This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
GLP-1 RA treatment was associated with a 37% increased risk of gallbladder or biliary diseases (RR, 1.37).
Why it matters
Understanding the risks associated with GLP-1 receptor agonists is crucial for patient safety, especially as these drugs are increasingly used for weight loss and diabetes management.
How the study worked
The study conducted a systematic review and meta-analysis of 76 randomized clinical trials comparing GLP-1 RAs to placebo or non-GLP-1 RAs.
What this study cannot tell us
The study is limited to data from randomized trials, which may not capture all real-world scenarios and long-term effects.
Read the original research
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
JAMA internal medicine, 182(5), 513-519
Citation
He, Liyun; Wang, Jialu; Ping, Fan; Yang, Na; Huang, Jingyue; Li, Yuxiu; Xu, Lingling; Li, Wei; Zhang, Huabing. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.. JAMA internal medicine, 182(5), 513-519. https://doi.org/10.1001/jamainternmed.2022.0338